BRAF, MEK Inhibition Shows Strong Long-Term Survival Benefit in Melanoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.

Updated survival data of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma, as well as analyses aimed at understanding patients who best responded to treatment were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 9502).

In this video, Caroline Robert, MD, PhD, of the Institut Gustave Roussy in Paris, discusses these new findings.

Recent Videos
Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.
David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.
David Rimm, MD, PhD, shared the rationale behind developing an AI-driven tool for quantifying tumor-infiltrating lymphocytes in melanoma.
The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content
A Prescription Drug User Fee Act date of April 10, 2026, has been established by the FDA based on a Class II resubmission timeline.

FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma

Tim Cortese
October 21st 2025
Article

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Second Primary Cancer Risk is Similar in Adjuvant Cemiplimab Vs Placebo in Skin Cancer Subtype

Second Primary Cancer Risk is Similar in Adjuvant Cemiplimab Vs Placebo in Skin Cancer Subtype

Jax DiEugenio
October 18th 2025
Article

Cemiplimab showed comparable rates of second primary tumors and improved disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

Caroline Seymour
October 18th 2025
Article

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

The most common any-grade TRAEs were fatigue (56%), diarrhea (33%), maculopapular rash (30%), pruritus (22%), anemia (19%), arthralgia (19%), and decreased lymphocyte count (19%).

Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma

Tim Cortese
October 15th 2025
Article

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.